The Pillar Post

Workshop: Single-vial amplification-based NGS to interrogate variants in tumors with limited diagnostic material

Workshop: Single-vial amplification-based NGS to interrogate variants in tumors with limited diagnostic material

November 14, 2018 by Bill Wright

Helen Fernandes, PhD, Co-director of Genomic Oncology at Columbia University, presented a talk on October 31, 2018 during the Corporate Workshop Day at the 2018 Association for Molecular Pathology (AMP) Annual Meeting in San Antonio, Texas.

 

In her talk, titled “Single-vial amplification-based NGS with rapid turn-around time for interrogation of variants in tumors with limited material”, Dr. Fernandes reviews the assays that her group at Columbia currently use and their rationale for including a customized gene panel. Dr. Fernandes then presents an overview of Pillar’s SLIMamp™ technology, the ONCOReveal Multi-Cancer Panel and the PIVAT Bioinformatics Analysis platform that her team used to test Pillar technology in their lab. Dr. Fernandes also presents performance data, specifically data on the accuracy, sensitivity and reproducibility of the validation assays. After sharing performance data on their custom Pillar panel, Dr. Fernandes shared that they will be submitting the assay for New York State approval by the end of the year.